An immunogenic composition comprising of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen, Hepatitis B surface antigen (HBsAg), inactivated whole-cell B. pertussis (wP) antigen, Haemophilus influenzae type B (Hib) capsular saccharide conjugated to a carrier protein, Inactivated Polio Virus (IPV) antigen and additionally one or more antigens and the method of preparing the same. A fully liquid combination vaccine, showing improved immunogenicity, reduced reactogenicity and improved stability. Improved methods of formaldehyde inactivation, improved adsorption profile of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen and Hepatitis B (HepB) surface antigen adsorbed individually onto aluminium phosphate adjuvant, minimum total aluminum content (Al.sup.3+) and optimized concentration of 2-phenoxyethanol (2-PE) as preservative.

Nucleic acid molecules encoding hepatitis B virus (HBV) surface antigens, HBV core antigens, and HBV polymerase antigens, and related combinations, are described. Also described are vectors, such as DNA plasmids or viral vectors, and RNA replicons, expressing the HBV antigens, and pharmaceutical compositions containing the expression vectors. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the pharmaceutical compositions of the invention are also described.

This application relates to methods for assessing patient populations and determining subpopulations vulnerable to viral infection, methods of reducing the risk of infection and/or inducing heterologous immunity to said viral infection.

One aspect relates to a pharmaceutical composition for the prevention or treatment of cancer or an anticancer immune vaccine composition, including a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1. The composition can enhance anticancer immunity by activating dendritic cells and T cells, and furthermore, can exhibit a remarkably excellent synergistic anticancer immune effect through administration in combination with an immune checkpoint inhibitor.

The present invention relates to a chimeric antigen, which binds specifically to target cells and enhances multiple immune functions, and the use thereof. Specifically, the present invention relates to: a chimeric antigen for inducing multiple immune functions wherein an immune response-inducing domain and a domain for inducing target cell-specific binding are fused to each other; a pharmaceutical composition for preventing or treating cancer, containing, as an active ingredient, the chimeric antigen for enhancing multiple immune functions; a pharmaceutical composition for preventing or treating infectious disease; a composition for enhancing immunity; and a vaccine composition.

The present disclosure relates to a fully liquid immunogenic composition comprising a combination of antigens/immunogens. The immunogenic composition comprises optimum amount of antigens/immunogens to confer protection against a number of diseases. The composition exhibits improved immunogenicity and stability. A process for preparing the vaccine composition is also disclosed.

Nanoparticles encapsulating polysaccharide conjugates and compositions comprising same are provided. Particularly the nanoparticles are prepared using a microfluidic device.

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

The present application provides immunotherapies for Hepatitis B virus infections. Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of Hepatitis B virus infections. Also provided herein are pharmaceutical compositions and methods for the treatment of Hepatitis B virus infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating Hepatitis B virus infection.

The present invention describes bioactive vitamin combinations that can be used in combination with other bioactive compounds, such as active drug ingredients or active vaccine components, to increase their therapeutic effects. The bioactive vitamin combinations comprise therapeutically effective amounts of L-Methylfolate, Adenosylcobalamin and Methylcobalamin.